Philippe Robaey

Philippe Robaey is a Professor in the Department of Psychology at the University of Ottawa with a joint appointment, serving as Chief Financial Officer of the Neuropsychiatry Research Laboratory at the Children's Hospital of Eastern Ontario (CHEO). His work integrates clinical neuropsychiatry, mental health research, and implementation science across international contexts.

His academic training includes:

• Doctor of Medicine (MD) in Medicine, Surgery and Midwifery from the Free University of Brussels (1978)
• PhD in Life and Health Sciences (Psychophysiology) from the University of Paris 6 (1987)

Robaey's research centers on ADHD heterogeneity and pharmacological treatment, utilizing computer modeling of dopamine-regulated neural circuits and precision medicine approaches. He pioneers implementation science for ADHD clinical pathways across cultures (e.g., China), employs brain imaging techniques (MRI, EEG, MEG), and develops genetic frameworks for ADHD. His work extends to pediatric cancer survivorship, examining neurocognitive outcomes in leukemia survivors through the PETALE study.

Analysis of his 15 most recent publications (2022-2025) reveals three dominant research axes: (1) ADHD treatment optimization via pharmacokinetic modeling and cross-cultural implementation; (2) long-term neurocognitive effects in childhood cancer survivors using genetic and neuroimaging biomarkers; and (3) neuromodulation safety and pandemic impacts on mental health. Key methodologies include computational modeling, exome-wide association studies, and neuroimaging biomarker development.

Robaey leads the Neuropsychiatry Research Laboratory at CHEO, directing interdisciplinary teams that bridge clinical practice, computational neuroscience, and global health implementation. His current projects focus on dopamine dysregulation mechanisms, cultural adaptation of mental health interventions, and survivorship care models for childhood cancer patients.